Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
Richard N van Zyl-SmitAliasgar EsmailMary E BatemanRodney DawsonJonathan GoldinEva van RikxoortMacaya DouoguihMaria Grazia PauJerald C SadoffJ Bruce McClainMargaret Ann SnowdenJacqueline BenkoDavid A HokeyKathryn Tucker RutkowskiAndrew GravesBarbara ShepherdSadritdin IshmukhamedovBenjamin M N KaginaBrian AbelWillem A HanekomThomas J ScribaEric D BatemanPublished in: American journal of respiratory and critical care medicine (2017)
Administration of the AERAS-402 candidate TB vaccine to participants with current or previous pulmonary TB induced a robust immune response and is not associated with clinically significant pulmonary complications. Clinical trial registered with www.clinicaltrials.gov (NCT 02414828) and in the South African National Clinical Trials Register ( www.sanctr.gov.za DOH 27-0808-2060).
Keyphrases
- clinical trial
- mycobacterium tuberculosis
- immune response
- pulmonary hypertension
- pulmonary tuberculosis
- phase ii
- open label
- double blind
- hiv aids
- high glucose
- phase iii
- diabetic rats
- risk factors
- quality improvement
- randomized controlled trial
- dendritic cells
- toll like receptor
- emergency department
- gene therapy
- placebo controlled
- antiretroviral therapy